GM-CSF Targeted Immunomodulation Affects Host Response to M. Tuberculosis Infection

Sulayman Benmerzoug,Fabio Vitarelli Marinho,Stéphanie Rose,Claire Mackowiak,David Gosset,Delphine Sedda,Emeline Poisson,Catherine Uyttenhove,Jacques Van Snick,Muazzam Jacobs,Irene Garcia,Bernhard Ryffel,Valerie F. J. Quesniaux

DOI: https://doi.org/10.1038/s41598-018-26984-3

IF: 4.6

2018-01-01

Scientific Reports

Abstract:Host directed immunomodulation represents potential new adjuvant therapies in infectious diseases such as tuberculosis. Major cytokines like TNFα exert a multifold role in host control of mycobacterial infections. GM-CSF and its receptor are over-expressed during acute M. tuberculosis infection and we asked how GM-CSF neutralization might affect host response, both in immunocompetent and in immunocompromised TNFα-deficient mice. GM-CSF neutralizing antibodies, at a dose effectively preventing acute lung inflammation, did not affect M. tuberculosis bacterial burden, but increased the number of granuloma in wild-type mice. We next assessed whether GM-CSF neutralization might affect the control of M. tuberculosis by isoniazid/rifampicin chemotherapy. GM-CSF neutralization compromised the bacterial control under sub-optimal isoniazid/rifampicin treatment in TNFα-deficient mice, leading to exacerbated lung inflammation with necrotic granulomatous structures and high numbers of intracellular M. tuberculosis bacilli. In vitro, GM-CSF neutralization promoted M2 anti-inflammatory phenotype in M. bovis BCG infected macrophages, with reduced mycobactericidal NO production and higher intracellular M. bovis BCG burden. Thus, GM-CSF pathway overexpression during acute M. tuberculosis infection contributes to an efficient M1 response, and interfering with GM-CSF pathway in the course of infection may impair the host inflammatory response against M. tuberculosis.